Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) a…

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...
Nature

This science sleuth revealed a retraction crisis at Indian universities

Agrawal explained that doing so was considered plagiarism — a serious violation of research integrity — but the student ...
C&EN

A trio of AI methods tackles enzyme design

RFdiffusion2, RFdiffusion3, and Riff-Diff each solve different structural problems in computational enzyme design ...